Login / Signup

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.

Ashley M HopkinsAkash D RathodAndrew RowlandGanessan KichenadasseMichael J Sorich
Published in: BMC cancer (2020)
Females had approximately two-fold increased risk of developing severe rash compared to males in clinical trials of vemurafenib alone or in combination with cobimetinib.
Keyphrases
  • clinical trial
  • early onset
  • phase iii
  • phase ii
  • drug induced
  • randomized controlled trial
  • study protocol
  • double blind